Protecting Human Health through Biotechnology Breakthroughs and Platforms

On November 15, 2020, after 4 months in large-scale Phase 3 clinical testing, Moderna received resounding proof that its new class of medicines based on messenger RNA encased in lipid nanoparticles could be safely deployed as a highly effective vaccine to combat the COVID-19 pandemic.
Source: News from the National Academies - Category: Science Source Type: news